Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New study seeks to unlock immune secrets behind deadly fungal infections in ICU patients

NCT ID NCT07130799

Knowledge-focused Sponsor: Central Hospital, Nancy, France Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at how the immune system responds in critically ill patients with severe abdominal infections. Researchers want to understand why some patients develop a serious fungal infection while others do not. They will measure a specific immune marker (HLA-DR) in 100 adults after emergency abdominal surgery. The goal is to improve early detection and risk assessment for fungal infections.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 100 people

The number the study aims to enrol. It can still change while the study runs.

Started

Nov 2025

Expected to finish

Mar 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

This study will include adult patients (≥18 years) admitted to the intensive care unit (ICU) for severe intra-abdominal infections requiring urgent abdominal surgery. Participants must present at least one recognized risk factor for intra-abdominal candidiasis, such as recent abdominal surgery, gastrointestinal perforation, healthcare-associated infection, immunosuppression, septic shock, or recent exposure to broad-spectrum antibiotics.

Ages

18 years and older

Sex

Anyone

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Adult patient (≥ 18 years old) * Patient admitted to the ICU or intermediate care unit for a severe intra-abdominal infection requiring urgent abdominal surgery * Presence of at least one risk factor for intra-abdominal candidiasis: * Abdominal surgery within the last 7 days * Supramesocolic gastrointestinal perforation * Healthcare-associated intra-abdominal infection * Community-acquired intra-abdominal infection in an immunocompromised patient\* * Intra-abdominal infection complicated by septic shock * Broad-spectrum antibiotic exposure within 72 hours prior to surgery * And/or a Peritonitis Score ≥ 3 out of 4 * Patient affiliated with or benefiting from a national health insurance system * Patient who has received full information about the clinical study Exclusion Criteria: * Radiologically guided drainage without surgery * Infected acute pancreatitis * Limitation or withdrawal of life-sustaining treatments * Moribund patient with an expected life expectancy \< 48 hours * Woman of childbearing potential without effective contraception * Refusal to participate in the study

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Candida sepsis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

candidemia candidiasis, invasive Critical Illness disseminated candidiasis infectious peritonitis Intraabdominal Infections Sepsis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Candida sepsis Critical illness Immunization; sepsis Intra-abdominal infection Post-op infection

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • CHRU de NANCY

    RECRUITING

    Vandœuvre-lès-Nancy, 54500, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.